Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets

Obesity and heart failure with preserved ejection fraction (HFpEF) represent two intermingling epidemics driving perhaps the greatest unmet health problem in cardiovascular medicine in the 21st century. Many patients with HFpEF are either overweight or obese, and recent data have shown that increased body fat and its attendant metabolic sequelae have widespread, protean effects systemically and on the cardiovascular system leading to symptomatic HFpEF. The paucity of effective therapies in HFpEF underscores the importance of understanding the distinct pathophysiological mechanisms of obese HFpEF to develop novel therapies. In this review, we summarize the current understanding of the cardiovascular and…

• UD
  U.S. Department of Defense

  Award: W81XWH2210245
• BH
  British Heart Foundation

  Award: FS/16/70/32157
• NI
  National Institutes of Health

  Awards: P30AG021332, U24AG059624, 1U01HL160272, R01AG18915, R01AG045551, U01 HL160226, R01 HL128526